JP5836373B2 - ビタミンｄの１４−エピ−アナログの新しい製剤 - Google Patents

ビタミンｄの１４−エピ−アナログの新しい製剤 Download PDF

Info

Publication number
JP5836373B2
JP5836373B2 JP2013519097A JP2013519097A JP5836373B2 JP 5836373 B2 JP5836373 B2 JP 5836373B2 JP 2013519097 A JP2013519097 A JP 2013519097A JP 2013519097 A JP2013519097 A JP 2013519097A JP 5836373 B2 JP5836373 B2 JP 5836373B2
Authority
JP
Japan
Prior art keywords
formulation
vitamin
oral
mct
epi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013519097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531024A (ja
Inventor
レミ・ドゥランソルネ
Original Assignee
ヒブリジェニクス・エスアー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10305783A external-priority patent/EP2407152A1/en
Priority claimed from US12/836,974 external-priority patent/US20120015913A1/en
Application filed by ヒブリジェニクス・エスアー filed Critical ヒブリジェニクス・エスアー
Publication of JP2013531024A publication Critical patent/JP2013531024A/ja
Application granted granted Critical
Publication of JP5836373B2 publication Critical patent/JP5836373B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013519097A 2010-07-15 2011-07-13 ビタミンｄの１４−エピ−アナログの新しい製剤 Expired - Fee Related JP5836373B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/836974 2010-07-15
EP10305783A EP2407152A1 (en) 2010-07-15 2010-07-15 Formulations of 14-epi-analogues of vitamin D
EP10305783.2 2010-07-15
US12/836,974 US20120015913A1 (en) 2010-07-15 2010-07-15 Formulations of 14-EPI-Analogues of Vitamin D
PCT/EP2011/061984 WO2012007517A1 (en) 2010-07-15 2011-07-13 Formulations of 14 - epi -analogues of vitamin d

Publications (2)

Publication Number Publication Date
JP2013531024A JP2013531024A (ja) 2013-08-01
JP5836373B2 true JP5836373B2 (ja) 2015-12-24

Family

ID=44281019

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013519097A Expired - Fee Related JP5836373B2 (ja) 2010-07-15 2011-07-13 ビタミンｄの１４−エピ−アナログの新しい製剤
JP2013519093A Expired - Fee Related JP5836372B2 (ja) 2010-07-15 2011-07-13 ビタミンｄの１４−エピ−アナログの新しい製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013519093A Expired - Fee Related JP5836372B2 (ja) 2010-07-15 2011-07-13 ビタミンｄの１４−エピ−アナログの新しい製剤

Country Status (18)

Country Link
EP (2) EP2407155B1 (da)
JP (2) JP5836373B2 (da)
KR (2) KR101821441B1 (da)
CN (2) CN103096877B (da)
AU (2) AU2011278352B2 (da)
BR (2) BR112013000930A2 (da)
CA (2) CA2805198C (da)
DK (2) DK2407155T3 (da)
ES (2) ES2401715T3 (da)
HR (2) HRP20130093T1 (da)
IL (2) IL224192A (da)
MX (1) MX2013000539A (da)
NZ (2) NZ606679A (da)
PL (2) PL2407155T3 (da)
PT (2) PT2407155E (da)
SG (2) SG187071A1 (da)
SI (2) SI2407155T1 (da)
WO (3) WO2012007517A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2805198C (en) * 2010-07-15 2018-07-31 Hybrigenics Sa New formulations of 14-epi-analogues of vitamin d and cmc
US20120015913A1 (en) 2010-07-15 2012-01-19 Delansorne Remi Formulations of 14-EPI-Analogues of Vitamin D
US20150246061A1 (en) * 2012-10-19 2015-09-03 Celus Pharmaceuticals, Inc. Vitamin d analogues for the treatment of a neurological disorder
WO2015193480A1 (en) * 2014-06-19 2015-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Composition comprising a combination of dna methylation inhibitor and a vitamin d receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse
WO2017211274A1 (en) * 2016-06-08 2017-12-14 Dong Yuhong Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE191712T1 (de) 1993-07-09 2000-04-15 Theramex Neue strukturelle vitamin d derivate
JPH10111593A (ja) * 1996-10-04 1998-04-28 Asahi Optical Co Ltd 複写機の変倍光学装置
US5936105A (en) 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
GB0305332D0 (en) 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
SG110107A1 (en) 2003-09-24 2005-04-28 Bioxell Spa Compound and use in treatment
GB0423091D0 (en) * 2004-10-19 2004-11-17 Leuven K U Res & Dev Bioactive vitamin d analogues
US20070093458A1 (en) * 2005-07-18 2007-04-26 Anchel Schwartz Preparation of paricalcitol and crystalline forms thereof
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
JP2010111593A (ja) * 2008-11-04 2010-05-20 Teijin Pharma Ltd １４−エピ−１９−ノルプレビタミンｄ３誘導体
NZ596497A (en) * 2009-05-20 2013-05-31 Hybrigenics Sa New therapeutical uses of inecalcitol
CA2805198C (en) * 2010-07-15 2018-07-31 Hybrigenics Sa New formulations of 14-epi-analogues of vitamin d and cmc

Also Published As

Publication number Publication date
EP2407155A1 (en) 2012-01-18
NZ606678A (en) 2014-11-28
JP2013531023A (ja) 2013-08-01
SG187071A1 (en) 2013-02-28
SI2407154T1 (sl) 2013-03-29
PL2407155T3 (pl) 2013-05-31
KR20130103709A (ko) 2013-09-24
ES2401715T3 (es) 2013-04-23
JP5836372B2 (ja) 2015-12-24
CA2805198C (en) 2018-07-31
BR112013000941A2 (pt) 2017-10-31
WO2012007517A1 (en) 2012-01-19
HRP20130237T1 (hr) 2013-04-30
KR20130089249A (ko) 2013-08-09
CA2805203A1 (en) 2012-01-19
CN103096876A (zh) 2013-05-08
DK2407155T3 (da) 2013-04-02
PL2407154T3 (pl) 2013-04-30
BR112013000930A2 (pt) 2017-10-31
RU2013106492A (ru) 2014-08-20
EP2407155B1 (en) 2012-12-26
DK2407154T3 (da) 2013-03-04
IL224191A (en) 2016-03-31
CA2805198A1 (en) 2012-01-19
AU2011278352B2 (en) 2016-07-21
MX2013000539A (es) 2013-04-11
RU2013106493A (ru) 2014-08-20
KR101821440B1 (ko) 2018-01-23
PT2407155E (pt) 2013-04-03
PT2407154E (pt) 2013-02-15
NZ606679A (en) 2014-07-25
WO2012007512A1 (en) 2012-01-19
KR101821441B1 (ko) 2018-01-23
WO2012007570A3 (en) 2012-05-24
IL224192A (en) 2016-02-29
AU2011278346B2 (en) 2016-04-07
JP2013531024A (ja) 2013-08-01
HRP20130093T1 (hr) 2013-02-28
AU2011278346A1 (en) 2013-03-07
AU2011278352A1 (en) 2013-03-07
SG187072A1 (en) 2013-03-28
ES2398640T3 (es) 2013-03-20
SI2407155T1 (sl) 2013-04-30
CN103096877B (zh) 2017-09-22
EP2407154B1 (en) 2012-11-07
CN103096877A (zh) 2013-05-08
EP2407154A1 (en) 2012-01-18
WO2012007570A2 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
UA120508C2 (uk) Комплекси сиролімусу і його похідних, спосіб їх отримання і фармацевтичні композиції, що містять зазначені комплекси
JP5836372B2 (ja) ビタミンｄの１４−エピ−アナログの新しい製剤
US12569505B2 (en) Oral solid dosage forms comprising cannabinoids
CN114344309A (zh) 一种别孕烷醇酮衍生物自乳化制剂及其制备方法
KR20200052280A (ko) 약학 조성물
US9314474B2 (en) Formulations of 14-epi-analogues of vitamin D
MXPA06006926A (es) Preconcentrado en microemulsion comprendiendo un inhibidor de renina.
CN103282022A (zh) 包含阿拉泊韦的药物组合物
EP2407152A1 (en) Formulations of 14-epi-analogues of vitamin D
RU2575792C2 (ru) Составы 14-эпи-аналогов витамина d
RU2575819C2 (ru) Новые составы 14-эпи-аналогов витамина d
AU3043400A (en) Cyclosporin solution
WO2000037083A1 (en) Oral antiestrogen pharmaceutical composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151102

R150 Certificate of patent or registration of utility model

Ref document number: 5836373

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees